Tezampanel

Drug Profile

Tezampanel

Alternative Names: LY 293558; NGX 424

Latest Information Update: 14 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly; Johns Hopkins University
  • Developer Raptor Pharmaceutical Corp
  • Class Analgesics; Antimigraines; Isoquinolines; Tetrazoles
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Migraine; Thrombosis

Highest Development Phases

  • Discontinued Migraine; Neuromuscular disorders; Thrombosis

Most Recent Events

  • 12 Aug 2014 Discontinued - Phase-I for Neuromuscular disorders in USA (SC)
  • 12 Aug 2014 Discontinued - Phase-I for Thrombosis (In volunteers) in USA (IV)
  • 12 Aug 2014 Discontinued - Phase-II for Migraine in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top